Ravioli Stocks

Sherwin-Williams to Webcast 2012 Year-End Financia

CLEVELAND, Dec. 14, 2012 (CRWENewswire)-- The Sherwin-Williams Company (NYSE:SHW) will issue a press release announcing its financial results for the fourth quarter and year ended December 31, 2012 prior to the opening of the market on Thursday, January 31, 2013. At that time, a copy of the press release and information regarding Sherwin-Williams' financial condition, operating segment results and other information will be available by clicking on this link http://investors.sherwin-williams.com/press/index.jsp , then clicking on the reference to the January 31st release.

The Company will conduct a conference call to discuss its financial results for the fourth quarter and full year 2012, and its outlook for the first quarter and full year 2013, at 11:00 a.m. ET on Thursday, January 31, 2013. Participating in the call will be Sherwin-Williams' Chairman and Chief Executive Officer, Christopher M. Connor, along with other senior executives.

The conference call will be webcast simultaneously in the listen only mode by Vcall. To listen to the webcast on the Sherwin-Williams website, click on this link http://investors.sherwin-williams.com/press/index.jsp , then click on the webcast icon following the reference to the January 31st release. The webcast will also be available at Vcall's Investor Calendar website, www.investorcalendar.com . An archived replay of the webcast will be available at this link http://investors.sherwin-williams.com/press/index.jsp beginning approximately two hours after the call ends and will be available until Thursday, February 21, 2013 at 5:00 p.m. ET.

Investor Relations Contact:
Bob Wells
Senior Vice President, Corporate Communications and Public Affairs
Sherwin-Williams
Direct: 216.566.2244
rjwells@sherwin.com

Media Contact:
Mike Conway
Director, Corporate Communications
Sherwin-Williams
Direct: 216.515.4393
Pager: 216.422.3751
mike.conway@sherwin.com

Source: The Sherwin-Williams Company

*********************************

R ead Full Disclaimer at http://www.crwenewswire.com/disclaimer

Frequency Electronics (FEIM) Q2 FY2013 Financial R

FEIM, Frequency Electronics, Inc.

** On its second quarter fiscal 2013, FEIM posted revenues of $17.6 million, a 17% increase year over year, and net income of $1.4 million or $0.17 per diluted share, compared to $768,000 or $0.09 per diluted share in the same period the prior year.

FEIM is a world leader in the design, development and manufacture of high precision timing, frequency control and synchronization products for space and terrestrial applications.

More about FEIM at www.frequencyelectronics.com

********************************

Read Full Disclaimer at http://pennyomega.com/disclaimer

3M Affirms 2012 EPS Expectations and Addresses 201

ST. PAUL, Minn.--(CRWENewswire)--On a conference call with analysts and investors, 3M (NYSE:MMM) today will affirm its 2012 earnings-per-share target of $6.27 to $6.35 and provide a roadmap for the company’s 2013 performance expectations.

3M anticipates 2013 earnings to be in the range of $6.70 to $6.95 per share with organic local-currency sales growth of 2 to 5 percent for the year. The company expects that free cash flow conversion will be in the range of 90 to 100 percent.

"I look forward to another strong year for 3M,” said Inge G. Thulin, 3M chairman, president and chief executive officer. "Our unique combination of technology, manufacturing prowess and global capability – along with inherent operational excellence – will enable us to once again grow sales and profits."

Today’s conference call will begin at 9:30 a.m. ET (8:30 a.m. CT). Investors can access the conference via the following:

* Live webcast at http://investor.3M.com

* Live telephone:
Call 800-762-2596 within the U.S. or +1 212-231-2916 outside the U.S.

* Webcast replay:
Go to 3M’s Investor Relations website at http://investor.3M.com and click on “2013 Outlook Conference Call.”

* Telephone replay:
Call 800-633-8284 (for both U.S. and outside the U.S.; access code is 21538829).
The telephone replay will be available until 10:00 a.m. CT on December 15, 2012.

Forward-Looking Statements
This news release contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "will," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic and capital markets conditions and other factors beyond the Company's control, including natural and other disasters affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) security breaches and other disruptions to the Company's information technology infrastructure; and (10) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and its subsequent quarterly reports on Form 10-Q (the "Reports"). Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Report). The information contained in this news release is as of the date indicated. The Company assumes no obligation to update any forward-looking statements contained in this news release as a result of new information or future events or developments.

About 3M
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $30 billion in sales, 3M employs 84,000 people worldwide and has operations in more than 65 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.

Contacts

3M
Investor Contacts:
Matt Ginter, 651-733-8206
or
Bruce Jermeland, 651-733-1807
or
Media Contact:
Jacqueline Berry, 651-733-3611

Source: 3M Company

*********************************

R ead Full Disclaimer at http://www.crwenewswire.com/disclaimer

Pernix Therapeutics to Acquire Somaxon Pharmaceuti

SOMX, Somaxon Pharmaceuticals, Inc.

** Pernix Therapeutics Holdings, Inc. and SOMX reported that they have entered into a definitive merger agreement for Pernix to acquire SOMX in a stock-for-stock transaction with a total equity value of $25 million.

Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, SOMX stockholders will receive aggregate consideration equal to $25 million in Pernix common stock.

SOMX is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area.

More about SOMX at www.somaxon.com

********************************

Read Full Disclaimer at http://pennyomega.com/disclaimer

Trius Therapeutics Completes Enrollment in Second

SAN DIEGO, Dec. 10, 2012 (CRWENewswire) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening infections, announced today that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

The pivotal Phase 3 trial, designated ESTABLISH 2, examines the efficacy and safety of a six-day course of tedizolid administered once a day versus a 10-day course of linezolid (Zyvox(R)) administered twice a day in patients recruited across sites in North and South America, Europe, Australia, New Zealand and South Africa. For both tedizolid phosphate and linezolid, drug was initially administered as an intravenous (IV) infusion with the option to switch to oral therapy after the initial day of therapy.

"As with our ESTABLISH 1 study, ESTABLISH 2 was designed to prepare tedizolid for registration globally by capturing both the new and former FDA endpoints as well as the European endpoints for ABSSSI," said Jeffrey Stein, Ph.D., President and Chief Executive Officer at Trius. "We remain on schedule to report top-line results from this study in early 2013. The tedizolid clinical program reflects our commitment to bring safe, well-tolerated and convenient therapies to people with life-threatening infections."

Last year, Trius completed its ESTABLISH 1 study, testing the oral dosing of tedizolid under the same trial design and endpoints as in ESTABLISH 2. The trial achieved all primary and secondary efficacy outcomes and showed significant safety and tolerability improvements versus linezolid.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The Company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated IND-enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of the two preclinical programs supported by federal contracts. For more information, visit www.triusrx.com .

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the expected timing of Trius' reporting of top-line results from the Establish 2 study. Risks that contribute to the uncertain nature of the forward-looking statements include: the accuracy of Trius' estimates regarding expenses, future revenues and capital requirements; the success and timing of Trius' preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Trius' plans to develop and commercialize its product candidates; Trius' ability to obtain additional financing; Trius' ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius' most recently filed SEC documents, including its Form 10-K, Forms 10-Q and other documents filed with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Public Relations Contact:
Laura Kempke/Andrew Law at MSLGROUP
trius@mslgroup.com
781-684-0770
Investor Relations Contact:
Stefan Loren at Westwicke Partners, LLC
sloren@westwicke.com
443-213-0507

Source: Trius Therapeutics, Inc.

*********************************

R ead Full Disclaimer at http://www.crwenewswire.com/disclaimer